BY TOPIC

Medical Monitoring

Practical perspectives on clinical judgment, patient safety, data review, trial execution, and the questions that arise throughout oncology clinical development.

MEDICAL MONITOR’S DESK ↓

PADAMOLOGY Q+A ↓

Perspectives on medical monitoring

Deeper insights into the clinical judgment, safety considerations, and real-world decisions behind the role.

From the Medical Monitor's Desk

Why Early Oncology Drug Development Requires a Different Mindset

Early oncology studies are not smaller versions of late-phase trials. They are exploratory environments where teams build knowledge patient by patient and must be comfortable making decisions before certainty exists.

When a Protocol Deviation Isn’t Just a Deviation

A missed assessment may be a simple operational deviation—or it may affect safety, data integrity, and how a study can be interpreted. The difference depends on context.

The Blind Spots in Early Oncology Development: The Risks We Don’t See Are Often the Ones That Matter Most

Early oncology development is full of unknowns, and the greatest risks are not always the ones already on the checklist. Strong teams learn to look for what the study may not yet be showing them.

Prior Lines of Therapy — The Detail That Changes Everything

“Prior lines of therapy” looks simple in an eligibility criterion until real patient histories are involved. What counts as a line can change eligibility, interpretation, and ultimately who enters the trial.

Debunking the Myths of Medical Monitoring

A CTCAE grade gives a toxicity a standardized label, but it cannot capture the full clinical story. Timing, trajectory, reversibility, context, and patient impact can matter just as much as the number.

CTCAE Grades Don’t Tell the Full Safety Story

Common Challenges in Oncology Trials and What We Actually Do About Them

Oncology trials rarely unfold without obstacles. The real work is not avoiding every challenge, but recognizing what matters, understanding the context, and making thoughtful decisions when the study gets complicated.

AI Won’t Replace Medical Monitors, But It Will Redefine How We Work.

AI can summarize, search, compare, and reduce administrative friction—but those tasks aren’t the heart of medical monitoring. The future belongs to clinicians who use AI to create more space for judgment.

A DLT Isn’t Just an Adverse Event—It’s One of the Most Important Decisions a Medical Monitor Makes

A dose-limiting toxicity is more than a protocol checkbox. DLT adjudication requires clinical context, pattern recognition, and judgment because one decision can shape the direction of an entire development program.

Medical Monitoring Isn’t Reactive and Treating It That Way Is Risky

Medical monitoring is most valuable before a safety signal becomes obvious. This launch issue explores why early recognition, clinical judgment, and proactive oversight matter in early development.

PADAMOLOGY Q+A

Questions about medical monitoring

Straightforward answers to common questions about the role, responsibilities, skills, and realities of medical monitoring.

Padamology Q+A

Q: Why do early phase oncology trials rarely go exactly as planned?

Early-phase oncology trials are designed around what we know at the start—but new information emerges quickly. Here’s why adaptation is often part of the process.

Q: Why are oncology protocols so complicated?

Oncology protocols can be exceptionally complex. Here’s what drives that complexity—and why much of it is necessary to safely answer the questions a trial is designed to address.

Q: What’s the difference between an SAE and a SUSAR?

SAEs and SUSARs are both critical to clinical trial safety—but they’re not the same thing. Here’s how they differ and why the distinction matters.

MORE TOPICS

Keep Reading

ONCOLOGY CLINICAL DEVELOPMENT →

PATIENT SAFETY →

LEADERSHIP + CAREERS →

PRECISION + ADVANCED THERAPIES →

CLINICAL TRIALS →

Looking for something else?

Find all Padamology articles, Q+As, and resources in one place.

Resource Hub